Literature DB >> 15527704

What is antiphospholipid syndrome?

Doruk Erkan1, Michael D Lockshin.   

Abstract

The description of antiphospholipid syndrome (APS) is vascular thrombosis and/or pregnancy morbidity occurring in persons with antiphospholipid antibodies (aPL). However, because of an unclear etiopathogenesis and the heterogeneous nature of aPL and of aPL-related clinical manifestations, a single, unambiguous definition of APS does not exist. In this paper, we describe a structured approach to APS, discuss the controversies, and offer descriptions of APS that include: an autoimmune systemic disease with a spectrum of (mostly thrombotic) clinical manifestations, an overdiagnosed disease when aPL is present but has no proven direct causative role in the clinical manifestations, and a disease of controversies that requires clarification of etiology and mechanisms and risk-stratified controlled clinical studies.

Entities:  

Mesh:

Year:  2004        PMID: 15527704     DOI: 10.1007/s11926-004-0024-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  59 in total

Review 1.  Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies.

Authors:  Azzudin E Gharavi; Silvia S Pierangeli; E Nigel Harris
Journal:  Immunobiology       Date:  2003       Impact factor: 3.144

2.  Systemic antiphospholipid syndrome.

Authors:  Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

3.  IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.

Authors:  S R Levine; L Salowich-Palm; K L Sawaya; M Perry; H J Spencer; H J Winkler; Z Alam; J L Carey
Journal:  Stroke       Date:  1997-09       Impact factor: 7.914

4.  Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus.

Authors:  D G Wahl; E De Maistre; F Guillemin; V Regnault; C Perret-Guillaume; T Lecompte
Journal:  QJM       Date:  1998-02

Review 5.  Thrombophilia and fetal loss.

Authors:  Benjamin Brenner
Journal:  Semin Thromb Hemost       Date:  2003-04       Impact factor: 4.180

Review 6.  Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.

Authors:  M I Bokarewa; M Blombäck
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

7.  Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models.

Authors:  S S Pierangeli; X Liu; R Espinola; T Olee; M Zhu; N E Harris; P P Chen
Journal:  Thromb Haemost       Date:  2000-09       Impact factor: 5.249

8.  Validation of the Sapporo criteria for antiphospholipid syndrome.

Authors:  M D Lockshin; L R Sammaritano; S Schwartzman
Journal:  Arthritis Rheum       Date:  2000-02

9.  Clinical consequences of antiphospholipid antibodies: an historic cohort study.

Authors:  R M Silver; M L Draper; J R Scott; J L Lyon; J Reading; D W Branch
Journal:  Obstet Gynecol       Date:  1994-03       Impact factor: 7.661

Review 10.  The role of complement in the antiphospholipid syndrome.

Authors:  Jane E Salmon; Guillermina Girardi
Journal:  Curr Dir Autoimmun       Date:  2004
View more
  7 in total

1.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

2.  Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab.

Authors:  G Tsagalis; E Psimenou; L Nakopoulou; A Laggouranis
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

3.  Assessment of the 2006 revised antiphospholipid syndrome classification criteria.

Authors:  Mala Kaul; Doruk Erkan; Lisa Sammaritano; Michael D Lockshin
Journal:  Ann Rheum Dis       Date:  2007-03-02       Impact factor: 19.103

Review 4.  Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature.

Authors:  M Sebastiani; C U Manzini; F Campomori; A Spinella; C Vacchi; D Giuggioli; D Giuggoli; F Schepis; C Ferri
Journal:  Clin Rheumatol       Date:  2013-03-13       Impact factor: 2.980

Review 5.  New approaches for managing antiphospholipid syndrome.

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Nat Clin Pract Rheumatol       Date:  2009-03

Review 6.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 7.  Neurological and Neuropsychiatric Manifestations of Antiphospholipid-Antibody Syndrome (APS).

Authors:  Saba Asif; Anoushka Bali; Ashujot Kaur Dang; Daniel A Gonzalez; Rajeswar Kumar
Journal:  Cureus       Date:  2022-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.